Koshinski Asset Management, Inc. Bei Gene, Ltd. Transaction History

Koshinski Asset Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 12, 2022	SELL	$121.11 - $216.05 $29,308 - $52,284	-242 Closed	0 $0
Q1 2022 Apr 20, 2022	BUY	$146.52 - $269.56 $20,659 - $38,007	141 Added 139.6%	242 $45.6 Million
Q4 2021 Jan 14, 2022	SELL	$248.56 - $389.34 $248 - $389	-1 Reduced 0.98%	101 $27.4 Million
Q3 2021 Oct 12, 2021	SELL	$249.6 - $403.14 $2.42 Million - $3.9 Million	-9,677 Reduced 98.96%	102 $37,000
Q4 2020 Feb 02, 2021	BUY	$221.31 - $316.61 $2.16 Million - $3.1 Million	9,779 New	9,779 $307,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Koshinski Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Koshinski Asset Management, Inc. with notifications on news.